In reply to @jianfcpku

In the last year, JN.1 and its subvariants quickly became dominant across the world and took over the XBB* lineages, which prompted us to investigate the immunogenicity and antigenicity of JN.1 lineage to help re-evaluate the global XBB-based vaccine strategy.(3/